Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Oncolytics Biotech Inc
T.ONC
Alternate Symbol(s):
ONCY
Healthcare
Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and...
adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:ONC)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(206)
•••
Buckhenry
X
View Profile
View Bullboard History
Comment by
Buckhenry
on Nov 13, 2024 1:14pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Today’s News
Pumpers working hard this morning trying to keep their base energized. Keep up the regurgitated mumbo jumbo.
(5316)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 13, 2024 1:11pm
RE:RE:Looming Big Pharma Patent Cliff
Conservatively, ONCY has stated the expected launch of pelareorep to be in 2027, and more realistically that can happen much sooner with the sponsor's expedited action in acquiring an Accelerated
...more
Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million
posted Nov 21, 2024 9:00am by
Innocan Pharma Corp
-
|
"Our strong operational and financial momentum continued throughout 2024 and now in the third quarter, we again demonstrated solid financial results. We are pleased to report nine consecutive quarters of continuous revenue growth. Our online platform continues to perform exceptionally well, contributing to our strong nine-month revenue growth of 174% YoY ...read more
(5316)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 13, 2024 12:50pm
RE:Big pharma is set to keep signing bigger deals in 2024
https://stockhouse.com/companies/bullboard?symbol=t.onc&postid=36310603
(5316)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 13, 2024 12:49pm
RE:Looming Big Pharma Patent Cliff
Takeaway : “Companies with sizable LOE exposure in 2025-2030 are under pressure to acquire assets that can be launched in coming years,”
(5316)
•••
Noteable
X
View Profile
View Bullboard History
Post by
Noteable
on Nov 13, 2024 12:47pm
Looming Big Pharma Patent Cliff
November 13, 2024 - "As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in acquiring external products with the potential
...more
(5316)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 13, 2024 12:38pm
RE:RE:Oncolytics Biotech® Reports Third Quarter 2024 Financial Res
https://stockhouse.com/companies/bullboard?symbol=t.onc&postid=36231069
(5316)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 13, 2024 12:34pm
RE:Oncolytics Biotech® Reports Third Quarter 2024 Financial Res
September 14, 2024 - Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study Final BRACELET-1
...more
(931)
•••
canadafan
X
View Profile
View Bullboard History
Post by
canadafan
on Nov 13, 2024 12:10pm
They sure try hard..look at the facts, not conjecture
" they" being the 3-4 constant FUDsters, who take every chance possible to trash the company. obviously not shareholders. notable posted 5 very clear, concise & accurate
...more
(23)
•••
m00nsh0ts
X
View Profile
View Bullboard History
Comment by
m00nsh0ts
on Nov 13, 2024 12:09pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Today’s News
CLDI was advertising on FOXBusiness over the last couple of months.
(185)
•••
CMHarring218431
X
View Profile
View Bullboard History
Comment by
CMHarring218431
on Nov 13, 2024 11:58am
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Today’s News
Certainly, a lot of volume for a company with less than 12 mil shares outstanding. Point being. They are a known entity. So many alternative therapies. Are they competiton for Oncy indirectly? Science
...more
(78)
•••
venture009
X
View Profile
View Bullboard History
Comment by
venture009
on Nov 13, 2024 11:27am
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Today’s News
Checkout CLDI, a potential competitor in the OV market. Getting huge traction on their glio therapy. To me they are years behind but rumor has it they are having great results with their trial.
(185)
•••
CMHarring218431
X
View Profile
View Bullboard History
Comment by
CMHarring218431
on Nov 13, 2024 11:09am
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Today’s News
Venture, Perhaps, that is exactly the point. Things are progressing with Oncy doing the work for now. When the cash crunch is imminent, one of the BP's steps in as the white knight when Oncy is
...more
(5316)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Nov 13, 2024 10:45am
RE:RE:RE:“Second mouse gets the cheese “
November 13, 2024 - Replimmune Completed Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) and remain on track to submit a BLA for RP1 plus nivolumab in
...more
(78)
•••
venture009
X
View Profile
View Bullboard History
Comment by
venture009
on Nov 13, 2024 10:45am
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Today’s News
It would seem securing a partner/buyout is becoming nothing more than a dream. BP know the ins and outs of this company and one would have expected some kind of offer by now if pela was as
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover Options Trading Strategies to Minimize your Tax Burden